According to Linden et al. FES PET/CT effectively assesses ER blockade by various endocrine therapies: FES tumor uptake was decreased to a greater extent by estrogen receptor blocking agents, i.e., fulvestrant and tamoxifen, than estrogen concentration-lowering agents—the aromatase inhibitors [79]. The gene discussed is ESR1; the disease is neoplasm.